NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2026)

NewAmsterdam Pharma has reported Current Deferred Revenue for 5 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 31.58% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 31.58% YoY) and the FY2025 annual result came in at $4.0 million, down 33.64% from the prior year.
• Current Deferred Revenue was little changed at $4.0 million in Q1 2026 per NAMS's latest filing, from $4.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $10.6 million in Q2 2023 and troughed at $13271.4 in Q4 2022.
• A 5-year average of $5.6 million and a median of $5.3 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 74956.26% in 2023, then tumbled 62.67% in 2025.
• Over 5 years, Current Deferred Revenue stood at $13271.4 in 2022, then soared by 74956.26% to $10.0 million in 2023, then sank by 39.68% to $6.0 million in 2024, then slumped by 33.64% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.0 million, $4.0 million, and $3.0 million for Q1 2026, Q4 2025, and Q1 2025 respectively.